Systems Biology Opens the Blackest Boxes
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Biopharma Job Outlook
The biopharma industry recently hit a rough patch with several major companies laying off workers. Roche is shutting down its Nutley, NJ, R&D site and planning to eliminate 1,000 jobs by the end of 2013. Novartis is planning to cut about 2,000 jobs nationwide, on top of 2,000 earlier European job cuts. AstraZeneca, Abbott, Takeda, Merck Serono, and Pfizer are also planning to lay off workers. However, there are possible silver linings: smaller biopharmas are expected to grow, and big pharma companies are beginning to hire new staff to cover areas left underserviced. So, how do you feel about your job stability right now?